Cite
APA Citation
Cho, B., Lin, J., Camidge, D., Velcheti, V., Solomon, B., Lu, S., Lee, K., Kim, S., Kao, S., Diadziuskzko, R., Beg, M., Nagasaka, M., Felip, E., Besse, B., Springfeld, C., Popat, S., Wolf, J., Trone, D., Stopatschinskaja, S., & Drilon, A. (n.d.). pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC). European journal of cancer, 174, S1–S2. http://access.bl.uk/ark:/81055/vdc_100168600225.0x000042